A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
Thomas Jefferson University
Thomas Jefferson University
Gilead Sciences
Henan Cancer Hospital
Chipscreen Biosciences, Ltd.
University College, London
Hackensack Meridian Health
Artiva Biotherapeutics, Inc.
University Hospital, Caen
Stanford University
Canadian Cancer Trials Group
City of Hope Medical Center
Gilead Sciences
SWOG Cancer Research Network
University of Chicago
Incyte Corporation
University of Miami
Hoffmann-La Roche
Allogene Therapeutics
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Seagen Inc.
Dana-Farber Cancer Institute
Institute of Hematology & Blood Diseases Hospital, China
Institute of Hematology & Blood Diseases Hospital, China
Gustave Roussy, Cancer Campus, Grand Paris
H. Lee Moffitt Cancer Center and Research Institute
National Institutes of Health Clinical Center (CC)
Gilead Sciences
Goethe University
Gilead Sciences
French Innovative Leukemia Organisation
Henan Cancer Hospital
Gilead Sciences
University of Arizona
Thomas Jefferson University
Baylor College of Medicine
Centre Antoine Lacassagne
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
Institut Bergonié
Universität des Saarlandes
Fate Therapeutics
Center for International Blood and Marrow Transplant Research
European Organisation for Research and Treatment of Cancer - EORTC
University of Miami
Massachusetts General Hospital
Cancer Trials Ireland
Masonic Cancer Center, University of Minnesota
National Institutes of Health Clinical Center (CC)
City of Hope Medical Center
National Institutes of Health Clinical Center (CC)